Biosimilars: Aligning Cost Savings with Clinical Outcomes

BIOSIMILARS HAVE moved from mere theoretical cost-saving alternatives to everyday clinical realities as biologic patents have expired, formularies were adopted and increased payer pressure was applied to reduce specialty drug spending. The economic rationale is well-established, but do those savings result in patients receiving equally effective care in real-world situations? In practice, the answer often depends on whether those cost savings make it easier for patients to start and stay on treatment without disruption. 

A patient requiring biologic therapy who previously faced high out-of-pocket costs may be more likely to initiate and continue treatment when a lower-cost biosimilar is available. However, these gains may not extend to patients who are already stable on their current biologic therapy. In those cases, switching to a lower-cost alternative due to insurance or formulary requirements may introduce uncertainty or disrupt continuity of care, potentially offsetting those gains.

These dynamics are not limited to a single condition or patient scenario. Across therapeutic areas — including oncology, gastroenterology and rheumatology — biosimilars are increasingly used both when treatment is started and throughout ongoing care. As their use expands, clinicians are encountering a range of outcomes shaped not only by clinical equivalence but also by how these therapies are introduced, maintained or substituted within existing treatment plans. 

A growing body of clinical and real-world evidence has begun to clarify these outcomes, demonstrating comparable efficacy, safety and immunogenicity across major therapeutic areas, as well as supporting the safe use of biosimilars in appropriately selected patients.

Clinical Outcomes

Across multiple studies and post-marketing analyses, biosimilars have demonstrated comparable efficacy, safety and immunogenicity to their reference biologics, with no clinically meaningful differences observed in the conditions for which they are approved — a requirement of the U.S. Food and Drug Administration. This consistency has been a key factor in supporting their broader integration into clinical practice.

A systematic review of 90 studies involving 14,225 patients across multiple diseases found no consistent differences in efficacy, safety or immunogenicity.¹ A randomized, double-blind NOR-SWITCH trial of 482 patients in the New England Journal of Medicine found no significant difference in disease worsening between reference infliximab and its biosimilar (CT-P13),²  supporting the safety of switching in appropriately selected patients.

Importantly, this evidence extends across major therapeutic areas, including oncology, rheumatology and gastroenterology, with biosimilars demonstrating consistent clinical performance in both patients starting treatment for the first time and those who have been previously treated.

Switching between a reference biologic and a biosimilar has also been examined in multiple clinical and real-world settings. Across these studies, transitions have not been associated with meaningful changes in efficacy, safety or immunogenicity in appropriately selected patients. While ongoing monitoring remains important, the available evidence suggests biosimilars can be used safely in both initiation and switching scenarios within routine clinical practice.³ 

Real-world studies and patient registry data have further supported these findings, demonstrating sustained efficacy and safety of biosimilars in routine clinical use across diverse patient populations. 

Cost Savings

Biosimilars offer a clear cost advantage over originator biologics, with lower acquisition prices driven by increased market competition following patent expiration. While the degree of price reduction varies by product and market, these differences can be substantial, particularly in high-cost therapeutic areas.

Biosimilars are typically 15 to 30 percent cheaper at launch, with deeper discounts over time as competition increases. Even so, these therapies remain costly. Insurance coverage generally offsets a significant portion of the expense, but patients are often responsible for coinsurance or deductible-based payments tied to the drug’s price. As a result, even a 15 to 30 percent reduction in price can translate into meaningful decreases in out-of-pocket spending, particularly for patients requiring long-term biologic therapy.

For example, a patient with rheumatoid arthritis who previously delayed starting a biologic due to annual treatment costs exceeding $50,000 may be able to begin therapy sooner when a lower-cost biosimilar becomes available. Improved formulary positioning in some cases may also reduce access barriers, allowing treatment to begin earlier and continue more consistently.

A similar dynamic can be seen in oncology, where the cost of biologic therapies can be substantial. A patient receiving treatment for HER2-positive breast cancer may require ongoing therapy with a monoclonal antibody. When a lower-cost biosimilar is available, reduced financial burden and improved formulary access may allow treatment to proceed without delay or interruption, which is critical for maintaining therapeutic effectiveness.

Beyond acquisition cost, the use of biosimilars has been associated with reductions in total cost of care for both health systems and patients. Lower drug spending can reduce overall treatment costs and give health systems greater flexibility in how resources are used. In practice, this may include expanding access to biologic therapies or easing treatment restrictions, with some resources redirected to other areas of care.

While manufacturer-sponsored assistance programs and nonprofit support may help reduce costs for some patients, access to these resources varies and does not eliminate financial barriers entirely.

Even so, reductions in drug costs can still have meaningful clinical implications for patients. Lower out-of-pocket costs may reduce financial barriers to treatment initiation and support greater adherence over time. 

For example, patients treated with a biosimilar infliximab have been shown to pay approximately 12 percent less out of pocket compared to those receiving the reference biologic. As biosimilars improve affordability and availability, their use has also been associated with greater treatment uptake and persistence in real-world settings. In chronic conditions requiring long-term biologic therapy, this can support more consistent treatment and reduce the likelihood of interruptions in care.

Impact on Patient Care

Beyond cost considerations, biosimilars influence how patients engage with treatment over time. Adherence is not solely a function of affordability, but also of patient confidence in the therapy being prescribed. Patients who understand their treatment plan and feel comfortable with changes ­— particularly when transitioning from a reference biologic — are more likely to remain consistent with therapy. Clear communication from physicians and care teams plays a critical role in maintaining that confidence.

Continuity of care is another important factor. For patients with chronic conditions, even small disruptions in treatment can affect disease control. While biosimilars have been shown to perform comparably to their reference products, changes in therapy, especially those driven by external factors such as formulary adjustments, may come with uncertainty. In these situations, maintaining a stable treatment plan and minimizing unnecessary changes can be just as important as the choice of therapy itself.

A patient with inflammatory bowel disease who has been stable for several years on a biologic therapy may be asked to transition to a biosimilar due to a formulary change. While clinical evidence supports comparable outcomes, the change itself can create uncertainty for the patient, particularly when symptoms have been well-controlled. Questions about effectiveness, potential side effects or loss of disease control may affect confidence in the treatment plan. In these situations, clear communication and careful monitoring can help make sure the transition is successful and that continuity of care is maintained.

Patient experience also extends to how and when treatment is initiated. Earlier access to biologic therapies may allow physicians and care teams to intervene before disease progression leads to irreversible damage. In conditions such as rheumatoid arthritis or inflammatory bowel disease, timely and sustained treatment can significantly influence long-term outcomes. Biosimilars, when integrated effectively into care plans, can support this earlier intervention without compromising clinical effectiveness.

Over time, the consistency of treatment can have a measurable impact on long-term outcomes. In chronic diseases, gaps in therapy or delayed initiation can contribute to disease progression, increased symptom burden and the need for more intensive interventions. By supporting more consistent access to biologic therapies, biosimilars may help reduce these risks and contribute to more stable disease management. In this way, their impact extends beyond immediate treatment decisions to influence the overall trajectory of care.

Physician Considerations

The integration of biosimilars into clinical practice increasingly requires physicians to consider both clinical and economic factors when making treatment decisions. While therapeutic equivalence is well-established, prescribing is often influenced by formulary design, coverage limitations and institutional cost-containment strategies. Incorporating biosimilars into cost-conscious prescribing does not require compromising clinical judgment but, rather, understanding when their use aligns with both patient needs and system constraints.

In addition to clinical and economic considerations, physicians must also determine when switching is appropriate on an individual patient basis. While evidence supports the safety of transitioning to biosimilars, factors such as disease stability, patient preference and prior treatment response should inform these decisions. For patients who are well controlled on a current biologic, the potential benefits of switching must be weighed against the risk of disrupting a stable treatment regimen. In these cases, shared decision-making becomes particularly important, allowing patients to participate in treatment choices and helping to maintain confidence in the care plan.

Effective patient communication is essential, particularly when initiating or transitioning therapy. Patients may have questions about the differences between biosimilars and the original brand-name biologic drug that the biosimilar is based on, especially when a change occurs after a disease has been stabilized for a period. For physicians to help maintain trust and support adherence, they need to address these concerns with clear, evidence-based explanations. In many cases, the way they communicate a treatment is as important as the decision itself.

Policies from organizations such as the Centers for Medicare and Medicaid Services and private insurers shape formulary preferences and coverage decisions, so physicians must also navigate ever-evolving payer rules. Familiarity with these frameworks can help clinicians anticipate treatment pathways and reduce administrative barriers to make sure patients receive timely and appropriate care within the constraints of the healthcare system.

Administrative considerations also play a role in biosimilar adoption. Prior authorization requirements, step therapy protocols and formulary changes can create additional workload for clinical teams and may delay treatment initiation or continuation. Understanding these processes and anticipating potential barriers can help streamline care delivery and reduce disruptions for patients. In many practices, coordination between physicians, pharmacists and support staff is essential to successfully integrating biosimilars into routine care.

Many practices are also turning to technology to manage these demands more efficiently, particularly for prior authorizations and payer communication. Artificial intelligence-driven tools can help automate parts of the documentation process, flag missing information before submission and streamline interactions with payers, reducing delays and administrative back-and-forth. In some settings, these tools are being integrated into electronic health record platforms to support more timely access to therapy while reducing the burden on clinical staff. 

Takeaway 

Biosimilars have demonstrated comparable clinical outcomes to their reference biologics while offering a clear opportunity to reduce the cost of care. Across multiple therapeutic areas, evidence from clinical trials and real-world studies has consistently shown no meaningful differences in efficacy, safety or immunogenicity. These findings have supported their growing role in routine clinical practice.

However, the impact of biosimilars is not determined by evidence alone. In practice, their success depends on how they are incorporated into treatment decisions, particularly in the context of patient stability, communication and system-level constraints. Decisions around initiation or switching must be made thoughtfully, considering both clinical factors and the broader realities of payer requirements and patient preferences.

As their use continues to expand, physicians play a central role in how biosimilars deliver on their promise. Through careful clinical judgment and clear communication, along with an understanding of the systems that shape access to care, clinicians can help translate cost savings into consistent, high-quality patient outcomes. In this way, the value of biosimilars is realized not simply through reduced spending, but through their effective integration into patient-centered care. Ultimately, their impact will be defined not by cost alone, but by how they are used in practice.